Inhibition of ERK phosphorylation in patients treated with the Raf kinase inhibitor BAY 43-9006

被引：0
|
作者：
Hilger, RA
Kredtke, S
Hedley, D
Moeller, JG
Voliotis, D
Stellberg, W
Seeber, S
Scheulen, ME
Strumberg, D
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Dept Internal Med, D-4300 Essen 1, Germany
[2] Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON, Canada
[3] Bayer AG, Clin Pharmacol, D-5600 Wuppertal, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
163
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.
    Veronese, ML
    Flaherty, KT
    Townsend, R
    Mosenkis, A
    Zimmer, R
    Rosen, M
    Gallagher, M
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 135S - 135S
  • [2] A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer
    Bankston, D
    Dumas, J
    Natero, R
    Riedl, B
    Monahan, MK
    Sibley, R
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2002, 6 (06) : 777 - 781
  • [3] Kinase inhibition with BAY 43-9006 n renal cell carcinoma
    Ahmad, T
    Eisen, T
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6388S - 6392S
  • [4] Bay-43-9006.: Oncolytic, Raf kinase inhibitor.
    Sorbera, LA
    Castañer, J
    Bozzo, J
    Leeson, PA
    DRUGS OF THE FUTURE, 2002, 27 (12) : 1141 - 1147
  • [5] Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum
    Afify, S
    Rapp, UR
    Högger, P
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 809 (01): : 99 - 103
  • [6] A phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 given orally to patients with solid tumors.
    Strumberg, D
    Bauer, RJ
    Moeller, JG
    Hilger, R
    Diaz-Carballo, D
    Richly, H
    Kredtke, S
    Beling, C
    Faghih, M
    Heinig, R
    Hedley, D
    Scheulen, ME
    Seeber, S
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3711S - 3711S
  • [7] A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers.
    Awada, A
    Hendlisz, A
    Gil, T
    Bleiberg, H
    Bartholomeus, S
    De Valeriola, D
    Dewitte, M
    Coppieters, S
    Moeller, J
    De Becker, D
    Meert, A
    Piccart, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [8] BAY 43-9006 inhibition of oncogenic RET mutants
    Carlomagno, F
    Anaganti, S
    Guida, T
    Salvatore, G
    Troncone, G
    Wilhelm, SM
    Santoro, M
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05): : 326 - 334
  • [9] Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
    Hirte, H
    Moore, M
    Hotte, S
    Oza, A
    Siu, L
    Harris, H
    MacLean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [10] Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
    Escudier, B
    Szczylik, C
    Eisen, T
    Stadler, WM
    Schwartz, B
    Shan, M
    Bukowski, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1093S - 1093S
12345